- Home
- CVKD vs GDTC Comparison
CVKD vs GDTC Comparison
Compare CVKD & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- GDTC
- Stock Information
- Founded
- CVKD 2022
- GDTC 2018
- Country
- CVKD United States
- GDTC Singapore
- Employees
- CVKD N/A
- GDTC N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- GDTC Health Care
- Exchange
- CVKD Nasdaq
- GDTC Nasdaq
- Market Cap
- CVKD 29.5M
- GDTC 28.0M
- IPO Year
- CVKD 2023
- GDTC 2023
- Fundamental
- Price
- CVKD $12.71
- GDTC $2.21
- Analyst Decision
- CVKD Strong Buy
- GDTC Buy
- Analyst Count
- CVKD 1
- GDTC 1
- Target Price
- CVKD $32.00
- GDTC $5.00
- AVG Volume (30 Days)
- CVKD 36.2K
- GDTC 6.6K
- Earning Date
- CVKD 08-06-2025
- GDTC 01-01-0001
- Dividend Yield
- CVKD N/A
- GDTC N/A
- EPS Growth
- CVKD N/A
- GDTC N/A
- EPS
- CVKD N/A
- GDTC N/A
- Revenue
- CVKD N/A
- GDTC $368,838.00
- Revenue This Year
- CVKD N/A
- GDTC $5.37
- Revenue Next Year
- CVKD N/A
- GDTC N/A
- P/E Ratio
- CVKD N/A
- GDTC N/A
- Revenue Growth
- CVKD N/A
- GDTC N/A
- 52 Week Low
- CVKD $5.70
- GDTC $1.20
- 52 Week High
- CVKD $22.90
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- CVKD 49.98
- GDTC 49.36
- Support Level
- CVKD $11.00
- GDTC $2.09
- Resistance Level
- CVKD $13.56
- GDTC $2.35
- Average True Range (ATR)
- CVKD 1.15
- GDTC 0.10
- MACD
- CVKD 0.25
- GDTC 0.00
- Stochastic Oscillator
- CVKD 80.97
- GDTC 50.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.